Talk Title: Mass spectrometry, proteomics and more
Dr Ralf Schittenhelm, Scientific Director, Proteomics Platform, Monash University
Ralf is the Director of the Monash Biomedical Proteomics which provide mass spectrometric expertise to the broader community. Ralf’s research has utilised high-resolution mass spectrometry to study the onset and progression of a variety of clinically relevant diseases known as spondyloarthropathies, which are inflammatory rheumatic disorders. In earlier work, Ralf worked in the team that identified and validated novel components of the insulin receptor / target of rapamycin (InR/TOR) pathway using mass spectrometric approaches in combination with biochemical assays.